Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing
Reexamination Certificate
2007-03-20
2011-12-06
Carlson, Karen (Department: 1656)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
C530S350000
Reexamination Certificate
active
08071533
ABSTRACT:
Compositions and methods for modulating activity of store-operated calcium entry in cells or tissues are provided. The compositions comprise the P311 protein, fused to a cell-penetrating peptide and formulated for delivery to tissues and cells. This protein has been shown to increase the levels of store-operated calcium entry (SOCE) in gingival cells, skeletal muscle cells, and prostate epithelial cells. Also provided are methods for preventing and treating diseases that involve administration of the P311 fusion protein, as well as methods for increasing levels of SOCE in cells.
REFERENCES:
patent: 2002/0111471 (2002-08-01), Lo et al.
patent: WO 00/31113 (2000-06-01), None
Deshayes et al., “Insight into the mechanism of internalization of the cell-penetrating carrier peptide Pep-1 through conformational analysis”, Biochemistry 2004 43:1449-1457.
Futaki, Shiroh, “Arginine-rich peptides:potential for intracellular delivery of macromolecules and the mystery of the translocation mechanisms”, International Journal of Pharmaceutics 2002 245:1-7.
Hashida et al., “Fusion of HIV-1 Tat protein transduction domain to poly-lysine as a new DNA delivery tool”, British Journal of Cancer 2004 90:1252-1258.
Ho et al., “Synthetic protein transduction domains:enhanced transduction potential in Vitro and in Vivo1”, Cancer Research 2001 61:474-477.
Morris et al., “Peptide carrier for the delivery of biologically active proteins into mammalian cells”, Nature Biotechnology 2001 19:1173-1176.
Schwartz et al., “Peptide-mediated cellular delivery”, Current Opinion in Molecular Therapeutics 2000 2(2):162-167.
Wadia et al., “Transducible TAT-HA fusogenic peptide enhances escape of TAT-fusion proteins after lipid raft macropinocytosis”, Nature Medicine 2004 10(3):310-315.
NCBI Accession No: NP—444308 [gi:16716357] with revision history—Nov. 1, 2001-Aug. 6, 2006.
Wadia et al., “Protein transduction technology”, Current Opinion in Biotechnology 2002 13:52-56.
Ma Jianjie
Pan Zui
Weisleder Noah
Carlson Karen
Licata & Tyrrell P.C.
University of Medicine and Dentistry of New Jersey
LandOfFree
Compositions and methods for modulating store-operated... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compositions and methods for modulating store-operated..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions and methods for modulating store-operated... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4266974